Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical AnalysisDefense World · Oct 16, 2026
Outlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerGlobeNewsWire · Oct 9, 2026
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor DiscussionGlobeNewsWire · Oct 6, 2026
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)GlobeNewsWire · Oct 1, 2026
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted TreatmentBusiness Wire · Sep 22, 2026
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)Defense World · Sep 16, 2026Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.08 | -$0.09 | Miss |
| May 15, 2026 | -$0.12 | -$0.16 | Miss |
| Feb 17, 2026 | -$0.17 | -$0.22 | Miss |
| Dec 19, 2025 | -$0.23 | -$0.22 | Beat |
| Aug 14, 2025 | -$0.42 | -$0.44 | Miss |
| May 15, 2025 | -$0.55 | -$0.40 | Beat |